Clinical Trials on Orthomyxoviridae Infections

Total 56384 results

Emory University

Recruiting

Influenza Human Challenge Model

Influenza

United States
University of Pennsylvania
National Institute of Allergy and Infectious Diseases (NIAID); Stanford University and other collaborators

Recruiting

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

Influenza, Human

United States
Bassett Healthcare
Genentech, Inc.; Viroclinics Biosciences B.V.

Recruiting

COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1) (COMBO 1)

Influenza

United States
University of Alabama at Birmingham

Recruiting

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

Influenza

United States
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

Influenza

United States
Mahidol University
The Government Pharmaceutical Organization (GPO) Bangkok, Thailand

Active, not recruiting

Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais

Influenza

Thailand
Seqirus

Completed

A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine

Influenza, Human

Estonia, Philippines
Centers for Disease Control and Prevention
Naval Medical Research Unit- 6; Peruvian Clinical Research; Hospital Nacional... and other collaborators

Active, not recruiting

Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP (EDUCATE)

Influenza

Peru
Osivax
Novotech (Australia) Pty Limited; Mater Misericordiae Limited

Completed

Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.

Influenza

Australia
GlaxoSmithKline

Completed

Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season

Influenza, Human

Germany, Spain, Belgium
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Influenza

China
The University of Hong Kong
Centers for Disease Control and Prevention

Active, not recruiting

Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong (PIVOT)

Influenza, Human

China
Ab&b Biotechnology Co., Ltd.JS
Henan Center for Disease Control and Prevention

Completed

A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months

Influenza

China
Centers for Disease Control and Prevention
University of Michigan; Rabin Medical Center; Soroka University Medical Center; Abt Associates and other collaborators

Completed

Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel

Influenza

Israel
Ology Bioservices

Completed

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

Influenza

United States
Butantan Institute
Butantan Foundation

Active, not recruiting

Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine

Influenza, Human

Brazil
Seqirus

Completed

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

Influenza, Human

United States, Estonia, Germany
Osivax
Center for vaccinology (CEVAC), University of Ghent

Completed

Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.

Influenza

Belgium
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years

Influenza, Human

China
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Completed

The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults

Influenza

United Kingdom
Geisinger Clinic

Completed

Flu Shot Pre-visit Questionnaire

Influenza

United States
Vietnam Military Medical University
Vietstar Biomedical Research; Institute of Vaccines and Medical Biologicals...

Completed

This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam

Influenza

Vietnam
CureVac
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults

Influenza

Panama
Mayo Clinic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Gene Signatures of Influenza Vaccine Responses in Older Adults

Influenza

United States
Public Health England

Withdrawn

Childhood Influenza Immunisation Invitation Trial in Schools

Influenza, Human
Marshfield Clinic Research Foundation
Centers for Disease Control and Prevention

Active, not recruiting

Randomized Influenza Vaccine Evaluation of Immune Response (RIVER)

Influenza

United States
Canadian Immunization Research Network
CHU de Quebec-Universite Laval; McGill University Health Centre/Research Institute... and other collaborators

Completed

CT18 Infant Influenza Priming Study in Vaccine Naive Infants

Influenza

Canada
University Hospital, Basel, Switzerland

Completed

Prospective System Analysis of the Seasonal Influenza Virus Transmissions and Evolution in the City of Basel Basel

Influenza
Henry M. Jackson Foundation for the Advancement...

Completed

Self-Administered Nasal Influenza Feasibility Study (SNIF)

Influenza

United States
Novavax

Completed

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

Influenza

United States
University of California, Los Angeles
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- UCLA Portal R/R Influenza RCT 3

Respiratory Tract Infections | Influenza

United States
Vaxart
Biomedical Advanced Research and Development Authority

Completed

A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

Influenza

United States
Osivax
Centre for vaccinology (CEVAC), University of Ghent

Completed

Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years

Influenza

Belgium
Osivax
Center for vaccinology (CEVAC), University of Ghent, Belgium

Completed

A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness.

Influenza

Belgium
Romark Laboratories L.C.

Completed

A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza

Influenza

United States, Australia, Puerto Rico
Hospices Civils de Lyon

Completed

Biomarkers for the Prognosis of Influenza in Children (BMIG)

Influenza

France
Wuhan Institute of Biological Products Co., Ltd

Active, not recruiting

To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years (QIV)

Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring (VAP00007)

Influenza

United States
SK Bioscience Co., Ltd.

Completed

Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months

Influenza

Korea, Republic of
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.

Influenza

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (QHD04)

Influenza

United States, Canada
Sanofi Pasteur, a Sanofi Company
Sanofi K.K.

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years

Influenza

Japan
Jiangsu Province Centers for Disease Control and...
Jiangsu Jindike Biotechnology Co., Ltd.

Enrolling by invitation

A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years

Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations (GRC90)

Influenza

United States
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old

Influenza

Russian Federation
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)

Influenza

Australia
MedImmune LLC

Completed

Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age

Influenza

United States, United Kingdom, Belgium, Czechia, Hong Kong, Ireland, Korea, Republic of, Taiwan
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial With Influenza A/H1N1 Vaccines

Influenza

China

3

Subscribe